AI assistant
Oric Pharmaceuticals, Inc. — Director's Dealing 2022
Dec 17, 2022
32131_dirs_2022-12-16_ee34d8a9-9efd-4e43-97c6-56ca087f1c98.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2022-12-15
Reporting Person: Multani Pratik S (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-15 | Common Stock | M | 6041 | $0.00 | Acquired | 9512 | Direct |
| 2022-12-15 | Common Stock | S | 2089 | $3.25 | Disposed | 7423 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-15 | Restricted Stock Unit | $ | M | 6041 | Disposed | Common Stock (6041) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
F2: Includes an aggregate of 3,471 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F3: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
F4: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.